1. Field of the Invention
The invention generally relates to medical devices and techniques, and more particularly to cardiovascular tissue closure devices and techniques.
2. Description of the Related Art
In most cardiology and radiology procedures, a catheter is inserted into an artery, such as the femoral artery, through a vascular introducer. When the procedure is complete, the physician removes the catheter from the introducer and then removes the introducer from the arteriotomy in the vessel. The physician then must prevent or limit the amount of blood that leaks through the arteriotomy so that the patient can be discharged. Physicians currently use a number of methods to close the arteriotomy, such as localized compression, sutures, collagen plugs, and adhesives, gels, foams, clips, and similar materials.
In performing localized compression, the physician presses down against the vessel to allow the arteriotomy to naturally clot. This method, however, can take a significant amount of time, and requires the patient to remain immobilized and be kept in the hospital for observation. Clots at the puncture site may also be dislodged. Moreover, the amount of time necessary for the compression can significantly increase depending upon how much heparin, glycoprotein IIb/IIA antagonists, or other anti-clotting agents were used during the procedure. Sutures and collagen plugs can have procedure variability, can require time to close the vessel, and can necessitate a separate deployment device. Adhesives, gels, foams, and clips can have negative cost factors, can necessitate a complicated deployment process, and can have procedure variability.
A tissue closure system can include a deployment instrument and a sealing element. The deployment instrument can be slidably mounted to and guided by a tubular medical device. The deployment instrument can be advanced over the tubular medical device to the desired location. The sealing element can then be advanced off of the end of the tool. The sealing element can include tissue engaging elements that are configured to automatically close upon deployment to bring together tissue. A slidably attached guided skin (or other tissue) cutter can also be used if desired to facilitate entry of the deployment instrument.
The following description provides examples of certain embodiments for purposes of illustration. The inventions as claimed should not be limited to these examples. Moreover, although the examples are provided in the context of vessel closure, the invention also has broad application to other types of tissue closure. U.S. Pat. No. 7,025,776 to Houser et al., the entirety of which is incorporated herein by reference, discloses a variety of additional vessel closure devices and methods with features that can be used in combination with or instead of features of the embodiments disclosed herein.
Referring to
The deployment instrument 104 can be guided by a tube section 110 of vascular introducer 108 through the percutaneous opening 112 until it reaches arteriotomy site 114. The deployment instrument 104 is configured to deploy a vascular closure clip 102 to close the arteriotomy 114. The deployment instrument 104 can then be withdrawn.
Fingers 122 and 124 can extend from base portion 120 and support a plurality of tissue-engaging elements such as tines 126a-b. In some embodiments, as illustrated, the fingers 122 and 124 can be positioned in a substantially opposing arrangement, for example wherein finger 122 is positioned in a substantially diametrically opposite location on the generally circular base 120 from finger 124. As explained below, many other positions and configurations can also be used.
In the illustrated example of
In some embodiments, the lengths 132, 133 can be selected so that the tines 126a, 126b pierce but do not completely penetrate through a vessel wall 116 of average thickness into the interior region of the vessel 118. For example, the length 132 may be greater than or equal to about 1 mm, and/or the length 132 may be less than or equal to about 4 mm, and the length 133 may be greater than or equal to about 1 mm, and/or the length 133 may be less than or equal to about 5 mm. In some embodiments, the length 132 is about 3 mm, and the length 133 is about 3 mm. In other embodiments, the tines 126a, 126b can be configured to penetrate the vessel wall, but generally not long enough to contact or penetrate the vessel wall 117 on the opposite side of the vessel 118. The lengths of the tines 126a, 126b are generally greater than the height 135 of the base portion 120. In the illustrated embodiment, fingers 122 and 124 are generally symmetrical about a central axis. In other embodiments, the fingers 122, 124 can be asymmetrical or include a different number or configuration of tissue-engaging elements.
Fingers 122, 124 can include one or more bend-facilitating regions 125, such as narrowed regions, indentations, articulating joints, or window portions as illustrated. The size, shape, and placement of the bend-facilitating regions 125 can be adjusted to assist in achieving a desired amount of closure force for the clip 102. As illustrated, the contours of the bend-facilitating regions 125 can be generally smooth to avoid additional trauma to the vessel wall. In some embodiments, an upper edge 129 of a bend-facilitating region 125 can be positioned in general alignment with a lower edge 131 of the base portion 120 to maintain a desired height 135 of the base portion 120. As illustrated, the width of the bend-facilitating region can be smaller than the height 135 of the base portion 120.
As illustrated, the height 136 of the support portions 141 of fingers 122 and 124 can be less than the length 133 of central tines 126a (for example, less than about 80%). This may permit the base portion 120 of the clip 102 to be positioned relatively close to the outer surface of the vessel wall 116 when the clip 102 is attached. In some embodiments, the support portions 141 can have different sizes or may be eliminated (e.g., with the tines 126a,b attaching directly to the base portion 120). In other embodiments, height 136 can be approximately equal to or greater than the length 133 of central tines 126a. The support portions 141 can include smoothly contoured sides 143, as illustrated, to diminish the likelihood that the support portions 141 will pierce the vessel wall 116 and/or cause trauma to the vessel wall 116. In the illustrated embodiment, the outer surface of the support portions 141 is curved (e.g., similar in curvature to the outer surface of the base portion 120). In some embodiments, the outer surface of the support portions 141 can be flat or can be shaped in a way different from the outer surface of the base portion 120.
Base portion 120 can define an outer diameter and an inner diameter. For example, the outer diameter can be greater than or equal to about 3 mm and/or less than or equal to about 7 mm, and the inner diameter can be greater than or equal to about 2.5 mm and/or less than or equal to about 6.5 mm. In some embodiments, the outer diameter is about 5.3 mm and the inner diameter is about 4.8 mm. Different size clips can be utilized depending on the specific tissue compression or closure application for which they are being used and to account for different anatomical sizes, such as differences in the thickness or diameter of the vessel wall 116. In some instances, a plurality of different-sized clips 102 can be provided to health care professionals to allow for variability and increased precision in diminishing trauma and increasing the appropriate closure force for a particular patient. Moreover, a clip size also can be selected to accommodate the tubular medical device over which the clip will be advanced. In embodiments effecting arteriotomy closure, the clip's inner diameter should be large enough to be advanced over a standard commercial introducer.
As illustrated in
For embodiments in which the base 120 is substantially circular, arc 406 corresponds to the circumferential width of fingers 122 and 124. In the illustrated embodiment, arc 406 subtends an approximately 90° angle. In some embodiments, arc 406 can subtend an angle greater than or equal to about 60° and/or less than or equal to about 90°. Other angles can also be used. Arc 403 corresponds to a circumferential width of window portions 125. In some embodiments, arc 403 can subtend an angle between greater than or equal to about 15° and less than or equal to about 30°. In certain embodiments, arc 403 can be less than or equal to about one-half the length of arc 406. Connecting portions of fingers 122 and 124 adjacent to the window portions 125 can have widths defined by arcs 402 and 404. Arc 139 corresponds to the separation distance between fingers 122 and 124. In the illustrated embodiment, arc 139 subtends an angle of approximately 90°. In some embodiments, arc 139 can subtend an angle greater than or equal to about 60° and/or less than or equal to about 90°. Other angles can also be used. In some embodiments, as illustrated, the shape and/or orientation of the base portion are substantially or entirely unchanged in the transition between an open or pre-deployed state and a closed or deployed state.
Distal end 173 of outer tube 156 can include an interior ledge or countersink 174 configured to receive and abut against the base 120 of clip 102. As will be explained in more detail below, when the assembled deployment instrument 104 is advanced to the tissue closure site and the inner tube 154 is axially withdrawn in the proximal direction from the outer tube 156, a distally directed reaction force is exerted by countersink 174 against the base 120 of the clip 102, preventing the clip 102 from also moving in the proximal direction. When the distal end 165 of the inner tube 154 is moved in the proximal direction past the base 120 of the clip 102, the contacting or adjacent relationship between the clip 102 and the inner and outer tubes 154, 156 is interrupted and the clip 102 is released from the deployment instrument 104. In certain embodiments, the use of countersink 174 can permit the outer tube 156 to avoid contact with or otherwise to protect all or a portion of clip 102 during advancement prior to deployment. In other embodiments, countersink 174 can be omitted and the distal-most surface of outer tube 156 can be configured to contact base 120 to force off or otherwise permit removal of the clip 102 from the deployment instrument 104.
The proximal end of inner tube 154 includes a handle 164 which may be gripped by the medical professional to withdraw inner tube 154 during deployment. As illustrated, handle 164 can be generally circular with a flattened lower end to facilitate delatching of the stop mechanism during complete deployment as explained below. Other shapes and configurations can also be used. The upper portion of handle 164 includes a cut-out portion 350 which is aligned with and merges with elongate slot 162. Lower portion of handle 164 includes a recess 169 to accommodate tab 172 of the outer tube 156. The distal end of handle 164 includes distal faces 354 which can be substantially flat. Faces 354 are configured to abut the proximal-most edge of the tube section of outer tube 156 to prevent over-insertion of inner tube 154 into outer tube 156. Proximal faces 167 of handle 164 can be substantially flat and are configured to abut stops 175 on tab 172 during partial deployment. Lower portion of the handle 164 can include angled surfaces 352.
A securing or movement-limiting structure such as tab 172 extends from a proximal end of outer tube 156. Tab 172 includes stop surfaces 175 configured to abut the proximal faces 167 on handle 164 during partial deployment as explained in more detail below. Tab 172 can include two tapered arms 181 surrounding a window portion 177 to facilitate assembly of the deployment instrument 104 as explained further below. Tab 172 can also include a recessed, weakened, or hinge portion 186 to facilitate bending. In certain embodiments, tab 172 can be relatively rigid with the exception of weakened portion 186. In certain embodiments, bending of tab 172 can be configured to occur substantially at weakened portion 186. In certain embodiments, tab 172 can be relatively long. For example, tab 172 can be at least about 20 mm. A long tab 172 can facilitate handling by the medical professional. A long tab 172 can also increase the leverage applied by the medical professional to effectuate bending.
The deployment instrument can include a pressure sensitive structure which can comprise, in one example, pressure tapers 178 formed on an outer surface of outer tube 56 and flexible tabs 188 of pressure element 158. Outer tube 156 can also include a pressure sensitive structure such as an axial protrusion 185 extending from a proximally-located outer surface. As illustrated, axial protrusion 185 can be located in a substantially diametrically opposite position from elongate slot 170, although other configurations are possible. A ramp or one-way tapered lock 184 extends from axial protrusion 185. A stop, 182 which can be generally annular in shape, extends from an outer surface of outer tube 156. The outer surface of outer tube 156 also includes pressure tapers 178. Pressure tapers 178 can terminate in substantially flat surfaces 180. Surfaces 180 can be adjacent to and in contact with annular stop 182. As illustrated, outer tube 156 can include two pressure tapers 178 located in a substantially diametrically opposite position from one another on the generally circular outer tube 156. Also as illustrated, pressure tapers 178 can be positioned at approximately equal circumferential distances from elongate slot 170 and axial protrusion 185. Other configurations are possible.
During assembly of deployment instrument 104, pressure element 158 can be advanced over the proximal end of outer tube 156 and over one-way tapered lock 184. Recessed portion 190 and/or lock 184 can be configured to flex or temporarily deform sufficiently to accommodate this procedure. Alternatively, lock 184 or other locking means can be formed on, or secured to, outer tube 156 after positioning of pressure element 158. Tapered lock 184 prevents pressure element 158 from moving too far in a proximal direction with respect to outer tube 156. Inner tube 154 can then be inserted into the inner lumen 171 of outer tube 156 from the outer tube's proximal end. As the inner tube 154 is inserted into outer tube 156, inner surfaces 183 (see
An example of a method for using deployment instrument 104 and clip 102 will now be described.
With reference to
With reference to
In some embodiments, other pressure-sensitive structures such as a pressure or force gauge can be utilized to verify that adequate pressure is being applied. The deployment instrument can utilize a spring in place of, or in addition to, a taper element. A first end of the spring can be secured to a slidable element. A second end can be attached to a distal point on the outer tube. The slidable element can be used to compress the spring, thus applying force to the outer tube. A combination or other means to confirm sufficient contact and pressure between the deployment instrument and vessel can also be included. In certain embodiments, the deployment instrument can include a grasping tool configured to assist in securing the distal end of the deployment instrument to the vessel. In certain embodiments, the medical professional can observe a backflow of blood through a channel or window in the deployment instrument following removal of the tubular medical device to confirm proper placement on the vessel. Blood can be configured to flow through the central channel of the deployment instrument. In certain embodiments, a clear channel can be provided to receive blood flow. One or more sensors can be provided to verify proper placement and/or pressure.
With the clip 102 partially deployed in the vessel wall 116, the tubular medical device 108 is no longer needed to guide the deployment instrument 104 to the arteriotomy and hence the tubular medical device 108 can then be removed from the vessel 118 as shown in
Once the tubular medical device 108 is removed from the vessel, the stops 175 can be overcome by bending tab 172 in the direction of the arrow 189 shown in
With reference to
In some embodiments, vascular closure system 100 can be completely or substantially extravascular in that the deployment instrument or closure device is not required to penetrate into the interior region of blood vessel 118. This reduces or eliminates the amount of foreign material introduced into contact with the patient's blood stream, thus reducing the risk of infection, blockage, or other complications. For example, in certain embodiments a posterior support is not required during deployment of the clip. In some systems, the use of posterior support may disadvantageously require that a portion of the deployment tool or closure device be positioned in the blood vessel during or following deployment. The use of a posterior support element within the vessel may require complicated mechanisms to facilitate its removal following deployment. The safe deployment of the clip without requiring posterior support can be facilitated through use of a partial deployment technique as described above and by the application of a controlled amount of external pressure via a pressure element or other pressure sensing means. In addition, the use of a clip with appropriately-sized tines to prevent overinsertion can also facilitate deployment without posterior support.
The system 100 described above can also be compatible with standard commercially available introducers already used in standard vascular interventional or diagnostic procedures. This can eliminate the need to purchase and use specialized and costly additional or different equipment or to change the way that the interventional or diagnostic procedures are performed, thus reducing the accompanying risks.
The removable clip 102 can be temporarily implanted utilizing the procedure outlined above. The proximal ends of the suture lines 234 can be left extending outside of the patient's body while the clip 102 remains implanted. After a period of time sufficient to achieve hemostasis, the medical professional can pull on the suture lines 234 to remove the clip as seen in
The time required to achieve hemostasis can vary from patient to patient depending on a variety of factors including the patient's age, sex, medical condition, medications, and the presence of anti-clotting agents that can have been used during the medical procedure. Under certain conditions, clip 102 can be removed after about 10 minutes, after about 20 minutes, or about 40 minutes.
In some embodiments, it can be desirable to use suture lines 234 even in clips intended for permanent implantation in order to enable emergency removal. In this arrangement, the medical professional can deploy the clip utilizing the procedure described above. Once it is determined that the clip has been successfully deployed, the medical professional can cut the suture lines 234 and completely withdraw them from around the clip.
The deployment instrument 104 can be partially or completely made from one or more of the following materials: polymers, including Nylon, polyamide, polycarbonate (e.g., Makrolon®), polyester, polyethleneteraphthalate (PET), polyetherethereketone (PEEK), polyimide, superelastic/shape memory polymers, metals including spring steel and stainless steel, metal alloys including Nitinol, 17-7 PH, Elgiloy, and Inconel, or ABS. Other suitable materials can also be used. The deployment instrument 104 can be completely or partially fabricated using one or more of the following methods: casting, extrusion, laminating, machining, molding (injection or other), sintering, stereo lithography. Other suitable methods can also be used.
As illustrated, in certain embodiments, the deployment instrument 104 can be constructed using relatively few components, e.g., an inner tube, an outer tube, and a pressure element. Each of the components can be produced inexpensively via injection molding. In certain embodiments, the deployment instrument 104 can be disposable and designed for single use. Alternatively, the deployment instrument 104 can be designed for repeated use following sterilization.
A method for loading the clip 102 onto the deployment instrument 104 will now be described with reference to
Slidable cutter 106 can include a channel 206 with a partial circumferential cross-sectional geometry as shown in
Frame 200 can include recesses 210 sized to receive scalpel blades 202. The recesses 210 can be used to shield portions of the blades 202 not intended to be used to cut tissue. Scalpel blades 202 can be secured to frame 200 via one or more of a variety of known methods such as, for example, friction-fitting, mechanical interference fitting, sonic welding, adhesives, screws, clamps, and the like. As illustrated, scalpel blades 202 are configured to angle inward toward one another slightly. Such a configuration can help to ensure that the blades 202 cut tissue immediately adjacent to the percutaneous opening 112. In other embodiments, scalpel blades 202 can be oriented in a substantially parallel configuration. In some embodiments, the blades 202 can be adjustable, allowing a medical professional to adjust one or more of the incision's depth, width, and angle, and/or a collection of cutters 106 of different sizes can be provided for different applications. In certain embodiments, slidable tissue cutter 106 is configured to cut substantially only the patient's skin. Fatty tissue located beneath the skin will generally move out of the way of the deployment instrument 104 with minimal resistance. Accordingly, a deeper incision may not be necessary in some embodiments.
The cutter 106 can be made from one or more of the following materials: polymers, including nylon, polyamide, polycarbonate (including Makrolon®), polyester, polyethyleneteraphthalate (PET), polyetheretherketone (PEEK), polyimide, superelastic/shape memory polymers, metals, including spring steel and stainless steel, and/or metal alloys including Nitinol, 17-7 PH, Elgiloy, Inconel, or ABS. Other appropriate materials can also be used. In embodiments utilizing a “snap-on” feature the frame 200 can be sufficiently flexible to allow the walls of the channel to bend outwardly to accommodate the tubular medical device 108. The slidable cutter 106 can be completely or partially fabricated using one or more of the following methods: casting, laminating, machining, molding (injection or other), sintering, stereo lithography. Other suitable methods can also be used. Advantageously, the slidable tissue cutter 106 can be inexpensive to produce and designed for one-time use. In other embodiments, the tissue cutter 106 can be designed for repeated use following sterilization. An additional advantage of slidable tissue cutter 106 is that it allows for greater precision and ease of use than a hand-held scalpel and is less dependent upon the medical professional's skill and care.
Tissue dilator 220 can include an elongate tubular portion 223 with a channel 222. Tubular portion 223 can include a tapered distal end 226 to facilitate insertion of tissue dilator 220 through the percutaneous opening 112. Tissue dilator 220 can include a base 221 with handle portions 224 extending beyond the end of channel 222. As illustrated, surfaces of handles 224 can be positioned in a plane generally parallel to a longitudinal axis of tubular portion 223. In other embodiments, handles 224 can be positioned at an appropriate angle, such as, for example, an angle of at least approximately 90 degree angle. Angled handles can advantageously provide a surface to push on that is perpendicular to the direction of applied force. As with the cutter 106, ends 228 of base 221 can act as mechanical stops to limit the depth of insertion. The medical professional can advance tissue dilator 220 until its distal end 226 encounters the resistance of the vessel wall 116. As with the cutter 106, channel 222 can have a partial circumferential cross-sectional geometry enabling it to “snap on” to an introducer sheath or other medical device. In other embodiments, a tissue dilator can utilize two mating pieces that clamp or snap together to facilitate temporary attachment and removal. In the illustrated embodiment, tubular section 221 includes a distal section 230 and a proximal section 232. Distal section 230 has a greater partial-circumferential cross-section than proximal section 232. In other embodiments, tubular section 221 can be substantially uniform along its length. Tissue dilator 220 can be made from materials and methods similar to those described above with reference to tissue cutter 106.
Clip 290 can provide more complete circumferential closure by being configured to engage tissue on substantially all sides of arteriotomy. In certain embodiments, it can be more desirable to use such clips 290 for permanent implantation and other clips for temporary implantation. For example, the use of only two opposed fingers can facilitate removal. The use of only two opposed fingers can create a “pinching”-type closing action which can be advantageously simple and predictable.
In certain embodiments, heat can be used to facilitate the closure of arteriotomy 114.
Heat can be used with any of the vascular closure clips described above, such as, for example clip 102. A power source 502 such as an RF power source is provided. Other suitable power sources such as a DC power source can also be used. Power source 502 is connected to a resistive element 508 via conductors 504 and 506. Clip 102 can function as the circuit's resistive element 508. In certain embodiments, only a portion of clip 102 will function as the resistive element. Clip 102 can be treated to increase its resistance value by, for example, being covered with a resistive coating. An increased resistance can reduce the power level necessary to effectuate a given amount of heating. In certain embodiments, portions of the clip 102 are covered with a thermally and/or electrically insulative coating. The remaining, uncovered portions of clip 102 can be configured to transfer thermal energy to the tissue being heated. In certain embodiments, only the tines or a distal portion of the tines are configured to transfer the thermal energy to the tissue. Conductors 504 and 506 can include wires made from a suitable electrically-conductive material such as copper-clad steel. In certain embodiments, conductors 504 and 506 can also function as tethering elements to allow removal of clip 102. Conductors 504 and 506 can be covered with an insulating cover or coating. A thermocouple 512 can be mounted to the clip to monitor the temperature of the clip and/or the surrounding tissue. The recorded temperature can be provided to a user display 510 and/or controller 514. Controller 514 permits the medical professional to adjust the amount of power delivered to the resistive element 508. In certain embodiments, the power delivered can be less than about 2 W, between about 2 and about 50 W, or greater than 50 W. The medical professional can maintain the tissue at the desired temperature for a certain length of time. In some embodiments, heat can be applied to the tissue for a period less than or equal to about 30 seconds, or greater than 30 seconds.
Following the application of heat, the conductors 504, 506 can be disconnected from clip 102 in many ways. For example, a twisting, cutting, or other manipulative action can be used to remove the conductors. In embodiments utilizing temporary or removable clips, conductors 504, 506 can be used as a primary or backup tethering element to remove the clip 102 following hemostasis. In certain embodiments, conductors 504, 506 can be connected to the clip 102 via spot welding, mechanical fit, soldering, combination, or other suitable method. Conductors 504, 506 can be fabricated from many different materials, such as copper, platinum, stainless steel, or a composite of materials (e.g. copper clad steel or platinum and silver combined by a drawn filled tubing process). In certain embodiments, conductors 504, 506 can include composite signal wires using silver as the inner core to better transmit, for example, radiofrequency or direct current energy. Conductors 504, 506 can be fabricated with a circular, elliptical, rectangular (flat), or other geometry which may depend on the space available on the clip 102. Conductors 504, 506 can be covered or jacketed with an insulative material such as polyimide, polyamide, polyurethane, polyester, nylon, or other suitable material.
In certain embodiments, a special tip can be placed over a standard electrosurgical tool such as, for example, a Bovie, to insert through the skin and make contact with the closure device and/or tissue. In certain embodiments, alternative heating means can be provided to heat the clip and/or the adjacent tissues including, for example, ultrasound energy, microwave energy, etc.
In another embodiment (not shown), a first portion of the clip can act as a first electrode and a second portion of the clip can act as a second electrode. The first and second portions of the clip can be electrically insulated from one another. For example, a first finger or a portion of the first finger such as one or more tines can act as the first electrode and a second finger or a portion of the second finger can act as the second electrode. A power source applies a voltage differential across the first and second electrodes causing current to flow between them and heat intervening tissue.
An electrode-enabled closure device can also be used to confirm contact between the closure device and the tissue surface, such as by comparing the impedance between an electrode element and a return path (indifferent electrode or second electrode). When an electrode surface contacts only or primarily blood, the measured impedance can be substantially higher than when a small or substantial portion of the electrode surface contacts tissue.
Other clip variations are also possible. The tissue compression can be modified by adjusting one or more of several tissue engagement element design attributes, such as the length, width, thickness, angle, number and location of the elements, etc. The proximal edge of the clip can have a straight, sinusoidal, notched, keyed, combination or other suitable design. The proximal edge geometry can mate with a contacting surface of the advancement and deployment instrument. Clips can be made from one or more of a tubing, sheet, wire, strip, band, rod, combination or other suitable material.
In certain embodiments, the clip can be configured to be in its malleable martensite phase at room temperature. The clip can be loaded onto a deployment instrument in an open configuration. The clip can be configured to transition to an austentite phase by the application of heat during or after deployment. The application of heat can cause the clip to revert to its memorized, closed configuration. In certain embodiments, the clip can be configured to revert to its closed configuration upon being heated to a temperature near the temperature of the human body. In such embodiments, the clip can be delivered to the arteriotomy and partially deployed or held in place on the exterior of the vessel wall 116 for a period of time sufficient to heat the clip to its austentite transition temperature. In other embodiments, heat may be applied via insertion of a heated probe or remotely via application of focused electromagnetic energy.
The clip can include at least one (single element) hinge feature to assist with deployment, tissue engagement, compression and or removal from the tissue. The clip can be partially or completely made from one or more of the following materials: metals including, spring steel and stainless steel, metal alloys including nitinol, 17-7 PH, Elgiloy, and Inconel. Other appropriate materials can also be used. In a preferred embodiment, the clip can be partially or completely made from a superelastic and/or shape memory material such as nitinol. A discussion of certain properties of superelastic and/or shape memory materials can be found in U.S. Pat. No. 7,182,771, the entirety of which is hereby incorporated by reference herein and made a part of the present specification. In certain embodiments, such as those utilizing nitinol or other superelastic and/or shape memory materials, it can be desirable for the clip to have a relatively tight bend in a memorized configuration. In some circumstances, it can be advantageous to use a bend sufficiently tight that it would normally exceed the elastic limit of the material and thus permanently deform it. To prevent permanent deformation, a bend can be produced in the device followed by an annealing process to relieve bending stresses within the device. Following this first bend, the device can be bent further to produce an even sharper bend, and then re-annealed to alleviate the stress from this additional bending. This process can be repeated to attain a desired substantial bend, or reduced radii, or reduced angle that would otherwise permanently deform the device if the bend were attempted in a single bending event. In certain embodiments, any surface of the clip that comes in contact with blood and/or tissue can be electropolished, especially metal or metal alloy surfaces, such as a superelastic/shape memory alloy. Electropolishing may be used to produce smooth surfaces. Electropolishing can also beneficially remove or reduces flash and other artifacts from the fabrication of the device.
The clip can have a completely contiguous cross section, or partial, incomplete contiguous cross section. A discontiguous cross-section can permit certain embodiments of the clips to be loaded from the side of the vascular introducer and/or deployment instrument. In certain embodiments, the deployment instrument can include a slot or opening permitting the deployment instrument to be secured to the tubular medical device from the side. Tissue engagement elements (e.g., tines, fingers, protrusions, etc.) can be parallel, overlapping, crossing, spiral, combination or other. The clip can include tissue engagement elements with the same, different or combination lengths. The clip can compress tissue on a horizontal plane, vertical plane or a combination of both. The tissue engagement elements can be straight, curved or a combination of both. The tissue attachment motion/direction can be straight, twisted, rotated, combination or other suitable and desirable motion or motions.
Swellable plug 310 can be partially or completely fabricated from materials that swell, or expand when they are exposed to a fluid, such as blood or subcutaneous fluid, or another fluid, for example, that can be added by the physician to cause the material to swell. These materials include hydrophilic gels (hydro gels), regenerated cellulose, polyethylene vinyl acetate (PEVA), as well as composites and combinations thereof and combinations of other biocompatible swellable or expandable materials. Thus, upon deployment, swellable plug 310 can swell causing longitudinal channel 318 to be occluded and sealing the arteriotomy. In certain embodiments, plug 310 can be partially or completely fabricated from a lyophilized hydrogel, such as, for example polyethylene gycol (PEG) or other polymer carrier. The polymer used in the carrier can include hydrolytically degradable chemical groups, thereby permitting in vivo degradation. Hydrophilic polymeric materials suitable for use in forming hydrogels include poly(hydroxyalkyl methacrylate), poly(electrolyte complexes), poly(vinylacetate) cross-linked with hydrolysable bonds, water-swellable N-vinyl lactams polyscaccharides, natural gum, agar, agarose, sodium alginate, carrageenan, fucoidan, furcellaran, laminaran, hypnea, eucheuma, gum Arabic, gum ghatti, gum karaya, gum tragacanth, locust beam gum, arabinogalactan, pectin, amylopectin, gelatin, hydrophilic colloids such as carboxymethyl cellulose gum or alginate gum crosslinked with a polyol such as propylene glycol, and the like. Several formulations of previously known hydrogels are described in U.S. Pat. No. 3,640,741 to Etes, U.S. Pat. No. 3,865,108 to Hartop, U.S. Pat. No. 3,992,562 to Denzinger et al., U.S. Pat. No. 4,002,172 to Manning et al., U.S. Pat. No. 4,014,335 to Arnold, U.S. Pat. No. 4,207,893 to Michaels, and in Handbook of Common Polymers, (Scott and Roff, Eds.) Chemical Rubber Company, Cleveland, Ohio, all of which disclosures in the foregoing patents and publication regarding hydrogels are incorporated herein by reference.
An example of a method for using plug deployment instrument 300 and plug 310 will now be described with reference to
As shown in
Swellable plug 310 can be shielded from unintended contact with fluid (blood, saline, etc.), before insertion into the body, by a removable wrapper or dissolvable coating. Swellable plug 310 can include a relatively rigid outer coating that begins to dissolve upon exposure to fluids such as blood, thus providing time for the medical professional to position the plug 310 within the arteriotomy. In some embodiments, a plug can be configured to be advanced directly over the tubular medical device 108 and deployment instrument 310 can be replaced with a pusher instrument. In certain embodiments, a plug can include a longitudinal slit or spiral allowing the plug to be attached to the tubular medical device or deployment instrument from the side. In certain embodiments, the deployment instrument can also include a slot allowing attachment from the side.
The vascular closure device can incorporate one or more coatings, materials, compounds, substances, drugs, therapeutic agents, etc. that positively affect healing at the site, at and or near where the device is deployed, either incorporated into the structure forming the device, incorporated into a coating, or both. Thromboresistance materials, antiproliferative materials, or other coatings intended to prevent thrombosis (acute and or chronic), hyperplasia, platelet aggregation, or other negative response, at or near the attachment of the device within the body. The coatings, materials, compounds, substances, drugs, therapeutic agents, etc. can be used by themselves, and/or contained in a carrier such as a polymeric matrix, starch, or other suitable material or method. The coatings can be liquid, gel, film, uncured, partially cured, cured, combination or other suitable form.
Many different types of delivery features, such as coatings on the vascular closure device, can be used to deliver therapeutic agents, including (but are not limited to) one or more of the following: antiproliferative/antimitotic agents including natural products such as vinca alkaloids (i.e. vinblastine, vincristine, and vinorelbine), paclitaxel, epidipodophyllotoxins (i.e. etoposide, teniposide), antibiotics (dactinomycin (actinomycin D) daunorubicin, doxorubicin and idarubicin), anthracyclines, mitoxantrone, bleomycins, plicamycin (mithramycin) and mitomycin, enzymes (L-asparaginase which systemically metabolizes L-asparagine and deprives cells which do not have the capacity to synthesize their own asparagine); antiplatelet agents such as G(GP) II.sub.b/III.sub.a inhibitors and vitronectin receptor antagonists; antiproliferative/antimitotic alkylating agents such as nitrogen mustards (mechlorethamine, cyclophosphamide and analogs, melphalan, chlorambucil), ethylenimines and methylmelamines (hexamethylmelamine and thiotepa), alkyl sulfonates-busulfan, nirtosoureas (carmustine (BCNU) and analogs, streptozocin), trazenes-dacarbazinine (DTIC); antiproliferative/antimitotic antimetabolites such as folic acid analogs (methotrexate), pyrimidine analogs (fluorouracil, floxuridine, and cytarabine), purine analogs and related inhibitors (mercaptopurine, thioguanine, pentostatin and 2-chlorodeoxyadenosine {cladribine}); platinum coordination complexes (cisplatin, carboplatin), procarbazine, hydroxyurea, mitotane, aminoglutethimide; hormones (i.e. estrogen); anticoagulants (heparin, synthetic heparin salts and other inhibitors of thrombin); fibrinolytic agents (such as tissue plasminogen activator, streptokinase and urokinase), aspirin, dipyridamole, ticlopidine, clopidogrel, abciximab; antimigratory; antisecretory (breveldin); anti-inflammatory: such as adrenocortical steroids (cortisol, cortisone, fludrocortisone, prednisone, prednisolone, 6.alpha.-methylprednisolone, triamcinolone, betamethasone, and dexamethasone), non-steroidal agents (salicylic acid derivatives i.e. aspirin; para-aminophenol derivatives i.e. acetominophen; indole and indene acetic acids (indomethacin, sulindac, and etodalac), heteroaryl acetic acids (tolmetin, diclofenac, and ketorolac), arylpropionic acids (ibuprofen and derivatives), anthranilic acids (mefenamic acid, and meclofenamic acid), enolic acids (piroxicam, tenoxicam, phenylbutazone, and oxyphenthatrazone), nabumetone, gold compounds (auranofin, aurothioglucose, gold sodium thiomalate); immunosuppressives: (cyclosporine, tacrolimus (FK-506), sirolimus (rapamycin), azathioprine, mycophenolate mofetil); angiogenic agents: vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF); angiotensin receptor blockers; nitric oxide donors; anti-sense oligionucleotides and combinations thereof, cell cycle inhibitors, mTOR inhibitors, and/or growth factor signal transduction kinase inhibitors. Alternatively, a clot promoter can be used, such as protamine sulphate or calcium hydroxide. Endothelial cells can also be added to the vascular closure device.
One or more of the therapeutic agents can be included in the device in many ways, such as by blending them into the device base materials during fabrication, applying them just prior to deployment, or applying them after the device has been deployed. One or more therapeutic agents can be used on a single device. The delivery feature can be designed to provide benefits rapidly or over an extended period of time. The delivery feature can be stable or eluting. The coatings, materials, compounds, substances, therapeutic agents, etc. can elute from a coated (or embedded) device (or component) over time and enter the surrounding tissue. In certain embodiments, the delivery feature can be effective during a period of at least about three days in some applications, between about seven and about thirty days in other application, and/or up to approximately six months in some applications.
Post device fabrication coating methods can include, but are not limited to, spin coating, RF-plasma polymerization, dipping, spraying, brushing, submerging the devices into a beaker containing a therapeutic solution while inside a vacuum chamber to permeate the device material, etc.
Alternatively, or in combination with the above therapeutic substances, one or more materials such as platinum, gold, tantalum, tin, tin-indium, zirconium, zirconium alloy, zirconium oxide, zirconium nitrate, phosphatidyl-choline, pyrolytic carbon, combination or other material, can be deposited onto the closure device surface using electroplating, sputtering vacuum evaporation, ion assisted beam deposition, vapor deposition, silver doping, boronation techniques, or other coating process.
Radiopaque material such as barium sulfate, bismuth trioxide, tantalum, platinum/iridium or other suitable materials can be added to any of the closure devices for enhanced visualization under a fluoroscope or other visualization means commonly used in a catheterization lab or surgical suite. Additionally, such materials can be added to the closure device by sputter coating, ion deposition, vapor deposition, combination, or other suitable processes.
In certain embodiments, the distal end of inner tube can have at least one section with a larger circumferential diameter or flare to cause clip tines to deflect outward (during forward movement during deployment), capturing more tissue (than without the increased diameter section) as the clip is advanced forward, for greater tissue compression and sealing. The distal end of the inner tube can also have a non circumferential enlargement such as at least one bump or raised surface arranged around the circumference. This design can be used to cause only some of the clip tines to be opened or deflected outward during advancement and deployment, or some to deflect more than others.
In certain embodiments, the deployment instrument can be configured so that the clip is deployed by advancing the outer tube distally relative to the inner tube instead of by proximally withdrawing the inner tube. The pressure element or other pressure sensing means can be secured to the inner tube, such as for example at a proximal end of the inner tube.
In certain embodiments, suction can be used to temporarily attach the deployment instrument to the vessel wall, and/or to confirm contact with the desired tissue. The deployment instrument can be configured to enable local and/or remote suction. In certain embodiments, an elongate suction tube or lumen can be secured to and/or located within the deployment instrument. The suction tube can include an opening on or near the distal end of the deployment instrument, and a valve or fitting (such as, for example, a Luer fitting) on the side or proximal end of the tool, to which a syringe, bulb, or other suction device could be attached and/or integrally formed. In certain embodiments, local suction can be accomplished without attachment to an external vacuum source. Local suction can be accomplished, for example, using a syringe or other physician manipulated device to pull a vacuum, creating the desired suction. A Luer-lock or stopcock then can be used to close the suction tube or lumen containing the vacuum to maintain a suction condition. In certain embodiments, a remote vacuum suction system can be attached to a vacuum line. The vacuum system can include a means for limiting the amount of vacuum/suction which can be created in order to prevent trauma to the tissue adjacent to the distal suction port.
The slidable tissue cutter can be adapted to use heat to cut skin and or other tissue by making the leading edge an electrode and attaching at least one electrical conductor to the electrode. Direct resistive element heating or ohmic tissue heating can be utilized. Biocompatible materials (e.g., gold, platinum, platinum/iridium, stainless steel, nitinol and other suitable materials) can be used for the electrode and connected to a suitable (e.g., electrical and biocompatible) conductor. For ohmic tissue heating, one conductor can be connected to an RF power source. Another conductor is connected to a ground pad placed on the patient's body, and also connected to the power source. For direct resistive element heating, both conductors from the power source are connected to an electrode.
In certain embodiments, the cutting elements of slidable tissue cutter can be designed to cut tissue or to both cut and remove tissue. In some cut-and-remove embodiments, the cutting element can be circular, diagonal, angled, or other blade. The slidable tissue cutter can be designed and utilized to cut any body tissue including, but not limited to, skin, fat ligaments, cartilage, bone, or vessels. The cutting element can be of any desirable type, including thermal (laser, RF, etc.), chemical, ultrasonic, combination, or other.
This disclosure has provided certain examples of closure devices including clips and plugs. However, other types of closure devices can be utilized. In certain embodiments, a closure device can be smaller in an initial configuration or in a deployed configuration. In certain embodiments, the closure device can close a tissue opening by bringing closer together sides of the tissue opening and/or by partially or completely occluding the opening. The closure device can be partially or completely made from one or more of a polymer, rubber, silicone, metal, metal alloy, or other suitable material or materials.
The closure device may be partially or completely fabricated from a biodegradable/bioabsorbable material, including but not limited to one or more of modified cellulose, collagen, fibrin, fibrinogen, fibronectin, elastin, vitronectin, laminin, thrombin, albumin and gelatin or other connective proteins or natural materials, polymers or copolymers such as polyvinyl pyrrolidone, polylactide [poly-L-lactide (PLLA), poly-D-lactide (PDLA)], polyglycolide, polydioxanone, polycaprolactone, polygluconate, polylactic acid (PLA), polylactic acid-polyethylene oxide copolymers, poly(hydroxybutyrate), polyanhydride, polyphosphoester, poly(amino acids), poly(alpha-hydroxy acid) poly d,l-lactic acid (PLA) and copolymers of lactic acid and glycolic acid (PLGA), or related copolymers of these materials as well as composites and combinations thereof and combinations of other biodegradable/bioabsorbable materials. The closure device can be partially or completely fabricated from a biocompatible material, such as expanded polytetrafluoroethylene (ePTFE), polyester, polyurethane, silicone, rubber, Dacron, and/or urethane.
The closure device can include one or more coatings and/or be partially or completely formed from one or more of the following: swellable materials, bioabsorbable materials, and biocompatible materials.
The closure device also can have a biocompatible contact surface such as an adhesive, bonding compounds, or other solutions located on any surface of the closure device. The contact surface can be applied or integrated into the device in many ways, such as during the manufacturing process, just prior to deployment, or after the device has been deployed. The bonding materials can be in the form of a liquid, semi solid, or solid. Suitable bonding materials can include gels, foams and microporous mesh. Suitable adhesives can include acrylates, cyanoacrylates, epoxies, fibrin-based adhesives, other biological based adhesives, UV light and/or heat activated or other specialized adhesives. The contact surface can bond on initial contact, or after a longer period of time to allow repositioning of the closure device if desired. Such a contact surface can include a crystalline polymer that changes from a non-tacky crystalline state to an adhesive gel state, such as when the temperature is raised from room temperature to body temperature. An example of such material is available under the trade name Intillemer™ adhesive, available from Landec Corp. as well as composites and combinations thereof and combinations of other materials. Suppliers of biocompatible adhesives include, but are not limited to, Plasto (Dijon, France), Haemacure (Montreal, Canada), Cohesion (Palo Alto, Calif.), Cryolife (Kennesaw, Ga.), TissueLink (Dover, N.H.), and others. To increase the work time of the contact surface and/or to allow repositioning of the closure device after it has been deployed, the contact surface can be blended with a material such as a starch or other material, that retards or delays bonding to allow repositioning of the coupler after it has been deployed. A degradable coating can be placed over the contact surface so that it degrades and exposes the adhesive. Other contact surfaces can include composites-based adherents and combinations of the above materials and other suitable materials as are known in the art.
Although the inventions have been disclosed in the context of certain preferred embodiments and examples, it will be understood by those skilled in the art that the present inventions extend beyond the specifically disclosed embodiments to other alternative embodiments and/or uses of the inventions and obvious modifications and equivalents thereof. Thus, it is intended that the scope of the present inventions herein disclosed should not be limited by the particular disclosed embodiments described above, but should be determined only by a fair reading of the claims that follow.
This application is related to and claims the benefit of U.S. Provisional 61/005,435, filed on Dec. 3, 2007, the entirety of which is hereby incorporated by reference herein and made a part of the present specification.
Number | Name | Date | Kind |
---|---|---|---|
3270745 | Charle | Sep 1966 | A |
3459189 | Alley et al. | Aug 1969 | A |
3675639 | Climber | Jul 1972 | A |
3702611 | Fishbein | Nov 1972 | A |
3859998 | Thomas et al. | Jan 1975 | A |
3874388 | King et al. | Apr 1975 | A |
3937733 | Ulbrich et al. | Feb 1976 | A |
4007743 | Blake | Feb 1977 | A |
4008720 | Brinckmann et al. | Feb 1977 | A |
4052989 | Kline | Oct 1977 | A |
4108175 | Orton | Aug 1978 | A |
4154226 | Hennig et al. | May 1979 | A |
4207870 | Eldridge | Jun 1980 | A |
4314555 | Sagae | Feb 1982 | A |
4317445 | Robinson | Mar 1982 | A |
4357846 | Primo | Nov 1982 | A |
4394373 | Malette et al. | Jul 1983 | A |
4447915 | Weber | May 1984 | A |
4468224 | Enzmann et al. | Aug 1984 | A |
4487605 | McGaughey et al. | Dec 1984 | A |
4525157 | Vaillancourt | Jun 1985 | A |
4543086 | Johnson | Sep 1985 | A |
4598711 | Deniega | Jul 1986 | A |
4610659 | Friese | Sep 1986 | A |
4610671 | Luther | Sep 1986 | A |
4645492 | Weeks | Feb 1987 | A |
4650488 | Bays et al. | Mar 1987 | A |
4652256 | Vaillancourt | Mar 1987 | A |
4654031 | Lentz | Mar 1987 | A |
4655750 | Vaillancourt | Apr 1987 | A |
4669473 | Richards et al. | Jun 1987 | A |
4710173 | McFarlane | Dec 1987 | A |
4738658 | Magro et al. | Apr 1988 | A |
4744364 | Kensey | May 1988 | A |
4770183 | Groman et al. | Sep 1988 | A |
4772264 | Cragg | Sep 1988 | A |
4774091 | Yamahira et al. | Sep 1988 | A |
4787391 | Elefteriades | Nov 1988 | A |
4792326 | Tews | Dec 1988 | A |
4832045 | Goldberger | May 1989 | A |
4836204 | Landymore et al. | Jun 1989 | A |
4852568 | Kensey | Aug 1989 | A |
4863431 | Vailancourt | Sep 1989 | A |
4890612 | Kensey | Jan 1990 | A |
4894052 | Crawford | Jan 1990 | A |
4904240 | Hoover | Feb 1990 | A |
4955890 | Yamamoto et al. | Sep 1990 | A |
4957105 | Kurth | Sep 1990 | A |
4959048 | Seder et al. | Sep 1990 | A |
4961729 | Vailancourt | Oct 1990 | A |
5021059 | Kensey et al. | Jun 1991 | A |
5030207 | Mersch et al. | Jul 1991 | A |
5035701 | Kabbara | Jul 1991 | A |
5053008 | Bajaj | Oct 1991 | A |
5053046 | Janese | Oct 1991 | A |
5059210 | Clark et al. | Oct 1991 | A |
5061274 | Kensey | Oct 1991 | A |
5074840 | Yoon | Dec 1991 | A |
5092841 | Spears | Mar 1992 | A |
5100416 | Oh et al. | Mar 1992 | A |
5108420 | Marks | Apr 1992 | A |
5108421 | Fowler | Apr 1992 | A |
5116357 | Eberbach | May 1992 | A |
5120319 | Van Heugten et al. | Jun 1992 | A |
5120527 | Li et al. | Jun 1992 | A |
5127626 | Hilal et al. | Jul 1992 | A |
5128121 | Berg et al. | Jul 1992 | A |
5160339 | Chen et al. | Nov 1992 | A |
5163959 | Herrick | Nov 1992 | A |
5171270 | Herrick | Dec 1992 | A |
5176653 | Metals | Jan 1993 | A |
5192301 | Kamiya et al. | Mar 1993 | A |
5201900 | Nardella | Apr 1993 | A |
5207691 | Nardella | May 1993 | A |
5209776 | Bass et al. | May 1993 | A |
5219353 | Garvey et al. | Jun 1993 | A |
5222974 | Kensey et al. | Jun 1993 | A |
5254133 | Seid | Oct 1993 | A |
5269809 | Hayhurst et al. | Dec 1993 | A |
5275616 | Fowler | Jan 1994 | A |
5283063 | Freeman | Feb 1994 | A |
5290310 | Makower et al. | Mar 1994 | A |
5292332 | Lee | Mar 1994 | A |
5292362 | Bass et al. | Mar 1994 | A |
5306234 | Johnson | Apr 1994 | A |
5314410 | Marks | May 1994 | A |
5324306 | Makower et al. | Jun 1994 | A |
5330445 | Haaga | Jul 1994 | A |
5333624 | Tovey | Aug 1994 | A |
5334137 | Freeman | Aug 1994 | A |
5334216 | Vidal et al. | Aug 1994 | A |
5342393 | Stack | Aug 1994 | A |
5350399 | Erlebacher et al. | Sep 1994 | A |
5350404 | Adams et al. | Sep 1994 | A |
5366459 | Yoon | Nov 1994 | A |
5370650 | Tovey et al. | Dec 1994 | A |
5376376 | Li | Dec 1994 | A |
5382899 | Funatsu et al. | Jan 1995 | A |
5383896 | Gershony et al. | Jan 1995 | A |
5383899 | Hammerslag | Jan 1995 | A |
RE34866 | Kensey et al. | Feb 1995 | E |
5391183 | Janzen et al. | Feb 1995 | A |
5405360 | Tovey | Apr 1995 | A |
5409499 | Yi | Apr 1995 | A |
5417651 | Guena et al. | May 1995 | A |
5419760 | Narciso | May 1995 | A |
5419765 | Weldon et al. | May 1995 | A |
5425757 | Tiefenbrun et al. | Jun 1995 | A |
5431639 | Shaw | Jul 1995 | A |
5433729 | Adams et al. | Jul 1995 | A |
5443463 | Stern et al. | Aug 1995 | A |
5443481 | Lee | Aug 1995 | A |
5443500 | Sigwart | Aug 1995 | A |
5447502 | Haaga | Sep 1995 | A |
5449375 | Vidal et al. | Sep 1995 | A |
5454834 | Boebel et al. | Oct 1995 | A |
5480388 | Zadini et al. | Jan 1996 | A |
5486195 | Myers et al. | Jan 1996 | A |
5529577 | Hammerslag | Jun 1996 | A |
5531759 | Kensey et al. | Jul 1996 | A |
5536251 | Evard et al. | Jul 1996 | A |
5556385 | Andersen | Sep 1996 | A |
5562617 | Finch, Jr. et al. | Oct 1996 | A |
5571181 | Li | Nov 1996 | A |
5573518 | Haaga | Nov 1996 | A |
5584801 | Kuroyanagi et al. | Dec 1996 | A |
5591189 | Yoon | Jan 1997 | A |
5591204 | Janzen et al. | Jan 1997 | A |
5593422 | Muijs Van de Moer et al. | Jan 1997 | A |
5601602 | Fowler | Feb 1997 | A |
5609604 | Schwemberger et al. | Mar 1997 | A |
5613974 | Andreas et al. | Mar 1997 | A |
5618297 | Hart et al. | Apr 1997 | A |
5620456 | Sauer et al. | Apr 1997 | A |
5620461 | Muijs Van De Moer et al. | Apr 1997 | A |
5624454 | Palti et al. | Apr 1997 | A |
5626601 | Gershony et al. | May 1997 | A |
5630833 | Katsaros et al. | May 1997 | A |
5634936 | Linden et al. | Jun 1997 | A |
5643318 | Tsukernik et al. | Jul 1997 | A |
5643596 | Pruss et al. | Jul 1997 | A |
5645553 | Kolesa et al. | Jul 1997 | A |
5645566 | Brenneman et al. | Jul 1997 | A |
5645568 | Chervitz et al. | Jul 1997 | A |
5645849 | Pruss et al. | Jul 1997 | A |
5649959 | Hannam et al. | Jul 1997 | A |
5653730 | Hammerslag | Aug 1997 | A |
5665106 | Hammerslag | Sep 1997 | A |
5665107 | Hammerslag | Sep 1997 | A |
5690674 | Diaz | Nov 1997 | A |
5697942 | Palti et al. | Dec 1997 | A |
5702421 | Schneidt | Dec 1997 | A |
5713859 | Finch, Jr. et al. | Feb 1998 | A |
5716375 | Fowler | Feb 1998 | A |
5718725 | Sterman et al. | Feb 1998 | A |
5723005 | Herrick | Mar 1998 | A |
5725498 | Janzen et al. | Mar 1998 | A |
5725551 | Myers et al. | Mar 1998 | A |
5733294 | Forber et al. | Mar 1998 | A |
5741223 | Janzen et al. | Apr 1998 | A |
5759194 | Hammerslag | Jun 1998 | A |
5766183 | Sauer | Jun 1998 | A |
5782860 | Epstein et al. | Jul 1998 | A |
5782861 | Cragg et al. | Jul 1998 | A |
5792173 | Breen et al. | Aug 1998 | A |
5797944 | Nobles et al. | Aug 1998 | A |
5797960 | Stevens et al. | Aug 1998 | A |
5810810 | Tay et al. | Sep 1998 | A |
5810884 | Kim | Sep 1998 | A |
5814066 | Spotnitz | Sep 1998 | A |
5814097 | Sterman et al. | Sep 1998 | A |
5830130 | Janzen et al. | Nov 1998 | A |
5830171 | Wallace | Nov 1998 | A |
5830222 | Makower | Nov 1998 | A |
5843108 | Samuels | Dec 1998 | A |
5843124 | Hammerslag | Dec 1998 | A |
5861003 | Latson et al. | Jan 1999 | A |
5861004 | Kensey et al. | Jan 1999 | A |
5865791 | Whayne et al. | Feb 1999 | A |
5868773 | Danks et al. | Feb 1999 | A |
5868778 | Gershony et al. | Feb 1999 | A |
5879403 | Ostiguy et al. | Mar 1999 | A |
5885258 | Sachdeva et al. | Mar 1999 | A |
5904703 | Gilson | May 1999 | A |
5906631 | Imran | May 1999 | A |
5941897 | Myers | Aug 1999 | A |
5948425 | Janzen et al. | Sep 1999 | A |
5957952 | Gershony et al. | Sep 1999 | A |
5964782 | Lafontaine et al. | Oct 1999 | A |
5972034 | Hofmann et al. | Oct 1999 | A |
5976174 | Ruiz | Nov 1999 | A |
5978704 | Ideker et al. | Nov 1999 | A |
5978705 | KenKnight et al. | Nov 1999 | A |
5979446 | Loy | Nov 1999 | A |
5984917 | Fleischman et al. | Nov 1999 | A |
5984950 | Cragg et al. | Nov 1999 | A |
5997580 | Mastrorio et al. | Dec 1999 | A |
6001110 | Adams | Dec 1999 | A |
6004347 | McNamara et al. | Dec 1999 | A |
6017359 | Gershony et al. | Jan 2000 | A |
6024755 | Addis | Feb 2000 | A |
6027470 | Mendius | Feb 2000 | A |
6042592 | Schmitt | Mar 2000 | A |
6042601 | Smith | Mar 2000 | A |
6045569 | Kensey et al. | Apr 2000 | A |
6045570 | Epstein et al. | Apr 2000 | A |
6056769 | Epstein et al. | May 2000 | A |
6056770 | Epstein et al. | May 2000 | A |
6063099 | Danks et al. | May 2000 | A |
6071281 | Burnside et al. | Jun 2000 | A |
6071300 | Brenneman et al. | Jun 2000 | A |
6079414 | Roth et al. | Jun 2000 | A |
6085119 | Scheiner et al. | Jul 2000 | A |
6090130 | Nash et al. | Jul 2000 | A |
6090135 | Plaia et al. | Jul 2000 | A |
6099506 | Macoviak et al. | Aug 2000 | A |
6110184 | Weadock | Aug 2000 | A |
6113608 | Monroe et al. | Sep 2000 | A |
6126675 | Shchervinsky et al. | Oct 2000 | A |
6132438 | Fleischman et al. | Oct 2000 | A |
6149684 | Herrick | Nov 2000 | A |
6152144 | Lesh et al. | Nov 2000 | A |
6156016 | Maginot | Dec 2000 | A |
6183496 | Urbanski | Feb 2001 | B1 |
6193733 | Adams | Feb 2001 | B1 |
6197042 | Ginn et al. | Mar 2001 | B1 |
6206893 | Klein et al. | Mar 2001 | B1 |
6206907 | Marino et al. | Mar 2001 | B1 |
6210366 | Sanfilippo | Apr 2001 | B1 |
6224618 | Gordon | May 2001 | B1 |
6224630 | Bao et al. | May 2001 | B1 |
6231561 | Frazier et al. | May 2001 | B1 |
6237605 | Vaska et al. | May 2001 | B1 |
6238363 | Kurihashi | May 2001 | B1 |
6241728 | Gaiser et al. | Jun 2001 | B1 |
6254562 | Fouere | Jul 2001 | B1 |
6258113 | Adams et al. | Jul 2001 | B1 |
6261309 | Urbanski | Jul 2001 | B1 |
6264673 | Egnelov et al. | Jul 2001 | B1 |
6277140 | Ginn et al. | Aug 2001 | B2 |
6280477 | Mastrorio et al. | Aug 2001 | B1 |
6287323 | Hammerslag et al. | Sep 2001 | B1 |
6296657 | Brucker | Oct 2001 | B1 |
6306114 | Freeman et al. | Oct 2001 | B1 |
6337995 | Mower | Jan 2002 | B1 |
6357443 | Loy | Mar 2002 | B1 |
6375662 | Schmitt | Apr 2002 | B1 |
6375671 | Kobayashi et al. | Apr 2002 | B1 |
6379366 | Fleischman et al. | Apr 2002 | B1 |
6383204 | Ferrera et al. | May 2002 | B1 |
6391048 | Ginn et al. | May 2002 | B1 |
6402770 | Jessen | Jun 2002 | B1 |
6423051 | Kaplan et al. | Jul 2002 | B1 |
6425911 | Akerfeldt et al. | Jul 2002 | B1 |
6436088 | Frazier et al. | Aug 2002 | B2 |
6436119 | Erb et al. | Aug 2002 | B1 |
6461364 | Ginn et al. | Oct 2002 | B1 |
6463317 | Kucharczyk et al. | Oct 2002 | B1 |
6464712 | Epstein et al. | Oct 2002 | B1 |
6474340 | Vaska et al. | Nov 2002 | B1 |
6482175 | Walker | Nov 2002 | B1 |
6485407 | Alferness et al. | Nov 2002 | B2 |
6488689 | Kaplan et al. | Dec 2002 | B1 |
6494848 | Sommercorn et al. | Dec 2002 | B1 |
6497651 | Kan et al. | Dec 2002 | B1 |
6502575 | Jacobs et al. | Jan 2003 | B1 |
6508828 | Akerfeldt et al. | Jan 2003 | B1 |
6511508 | Shahinpoor et al. | Jan 2003 | B1 |
6517575 | Yang et al. | Feb 2003 | B1 |
6537299 | Hogendijk et al. | Mar 2003 | B1 |
6546270 | Goldin et al. | Apr 2003 | B1 |
6547806 | Ding | Apr 2003 | B1 |
6549812 | Smits | Apr 2003 | B1 |
6551303 | Van Tassel et al. | Apr 2003 | B1 |
6561969 | Frazier et al. | May 2003 | B2 |
6589269 | Zhu et al. | Jul 2003 | B2 |
6596012 | Akerfeldt et al. | Jul 2003 | B2 |
6610026 | Cragg et al. | Aug 2003 | B2 |
6612069 | Locke et al. | Sep 2003 | B2 |
6613059 | Schatler et al. | Sep 2003 | B2 |
6623509 | Ginn | Sep 2003 | B2 |
6623510 | Carley et al. | Sep 2003 | B2 |
6626918 | Ginn et al. | Sep 2003 | B1 |
6629533 | Webb et al. | Oct 2003 | B1 |
6632238 | Ginn et al. | Oct 2003 | B2 |
6632239 | Snyder et al. | Oct 2003 | B2 |
6645205 | Ginn | Nov 2003 | B2 |
6645225 | Atkinson | Nov 2003 | B1 |
6652555 | Van Tassel et al. | Nov 2003 | B1 |
6652556 | VanTassel et al. | Nov 2003 | B1 |
6656207 | Epstein et al. | Dec 2003 | B2 |
6663655 | Ginn et al. | Dec 2003 | B2 |
6666861 | Grabek | Dec 2003 | B1 |
6669687 | Saadat | Dec 2003 | B1 |
6669714 | Coleman et al. | Dec 2003 | B2 |
6679904 | Gleeson et al. | Jan 2004 | B2 |
6681773 | Murphy et al. | Jan 2004 | B2 |
6682489 | Tenerz et al. | Jan 2004 | B2 |
6689150 | VanTassel et al. | Feb 2004 | B1 |
6699240 | Francischelli | Mar 2004 | B2 |
6702763 | Murphy et al. | Mar 2004 | B2 |
6702835 | Ginn | Mar 2004 | B2 |
6712837 | Akerfeldt et al. | Mar 2004 | B2 |
6716234 | Grafton et al. | Apr 2004 | B2 |
6719777 | Ginn et al. | Apr 2004 | B2 |
6726696 | Houser et al. | Apr 2004 | B1 |
6730020 | Peng et al. | May 2004 | B2 |
6730108 | Van Tassel et al. | May 2004 | B2 |
6732739 | Cosgrove | May 2004 | B2 |
6736815 | Ginn | May 2004 | B2 |
6743259 | Ginn | Jun 2004 | B2 |
6746461 | Fry | Jun 2004 | B2 |
6770026 | Kan et al. | Aug 2004 | B2 |
6776784 | Ginn | Aug 2004 | B2 |
6780197 | Roe et al. | Aug 2004 | B2 |
6786905 | Swanson et al. | Sep 2004 | B2 |
6786915 | Akerfeldt et al. | Sep 2004 | B2 |
6790218 | Jayaraman | Sep 2004 | B2 |
6793664 | Mazzocchi et al. | Sep 2004 | B2 |
6830576 | Fleischman et al. | Dec 2004 | B2 |
6846319 | Ginn et al. | Jan 2005 | B2 |
6860895 | Akerfeldt et al. | Mar 2005 | B1 |
6890343 | Ginn et al. | May 2005 | B2 |
6896692 | Ginn et al. | May 2005 | B2 |
6941169 | Pappu | Sep 2005 | B2 |
6949113 | Van Tassel et al. | Sep 2005 | B2 |
6959711 | Murphy et al. | Nov 2005 | B2 |
6969397 | Ginn | Nov 2005 | B2 |
6970742 | Mann et al. | Nov 2005 | B2 |
6994092 | van der Burg et al. | Feb 2006 | B2 |
6994093 | Murphy et al. | Feb 2006 | B2 |
7001398 | Carley et al. | Feb 2006 | B2 |
7008439 | Janzen et al. | Mar 2006 | B1 |
7011671 | Welch | Mar 2006 | B2 |
7025773 | Gittings et al. | Apr 2006 | B2 |
7025776 | Houser et al. | Apr 2006 | B1 |
7029838 | Williams et al. | Apr 2006 | B2 |
7044134 | Khairkhahan et al. | May 2006 | B2 |
7052492 | Swanson et al. | May 2006 | B2 |
7052829 | Williams et al. | May 2006 | B2 |
7056294 | Khairkhahan et al. | Jun 2006 | B2 |
7083614 | Fjield et al. | Aug 2006 | B2 |
7083635 | Ginn | Aug 2006 | B2 |
7112219 | Vidlund et al. | Sep 2006 | B2 |
7115095 | Eigler et al. | Oct 2006 | B2 |
7128073 | van der Burg et al. | Oct 2006 | B1 |
7128740 | Jacobs et al. | Oct 2006 | B2 |
7137953 | Eigler et al. | Nov 2006 | B2 |
7144411 | Ginn et al. | Dec 2006 | B2 |
7152605 | Khairkhahan et al. | Dec 2006 | B2 |
7169164 | Borillo et al. | Jan 2007 | B2 |
7182771 | Houser et al. | Feb 2007 | B1 |
7189199 | McCarthy et al. | Mar 2007 | B2 |
7192439 | Khairkhahan et al. | Mar 2007 | B2 |
7211048 | Najafi et | May 2007 | B1 |
7217284 | Houser et al. | May 2007 | B2 |
7226458 | Kaplan et al. | Jun 2007 | B2 |
7250057 | Forsberg | Jul 2007 | B2 |
7288090 | Swanson | Oct 2007 | B2 |
7293562 | Malecki et al. | Nov 2007 | B2 |
7297144 | Fleischman et al. | Nov 2007 | B2 |
7318829 | Kaplan et al. | Jan 2008 | B2 |
7326201 | Fjield et al. | Feb 2008 | B2 |
7327862 | Murphy et al. | Feb 2008 | B2 |
7335219 | Ashby et al. | Feb 2008 | B1 |
7335220 | Khosravi et al. | Feb 2008 | B2 |
7344543 | Sra | Mar 2008 | B2 |
7344553 | Opolski et al. | Mar 2008 | B2 |
7361183 | Ginn | Apr 2008 | B2 |
7427279 | Frazier et al. | Sep 2008 | B2 |
7429264 | Melkent et al. | Sep 2008 | B2 |
7455669 | Swanson | Nov 2008 | B2 |
7483743 | Mann et al. | Jan 2009 | B2 |
7575586 | Berg et al. | Aug 2009 | B2 |
7931671 | Tenerz | Apr 2011 | B2 |
8105352 | Egnelöv | Jan 2012 | B2 |
8118831 | Egnelöv et al. | Feb 2012 | B2 |
8157836 | Adams | Apr 2012 | B2 |
20010003158 | Kensey et al. | Jun 2001 | A1 |
20010003986 | Cosgrove | Jun 2001 | A1 |
20010007077 | Ginn et al. | Jul 2001 | A1 |
20010034509 | Cragg et al. | Oct 2001 | A1 |
20020019648 | Akerfeldt et al. | Feb 2002 | A1 |
20020022860 | Borillo et al. | Feb 2002 | A1 |
20020026208 | Roe et al. | Feb 2002 | A1 |
20020032454 | Durgin et al. | Mar 2002 | A1 |
20020049457 | Kaplan et al. | Apr 2002 | A1 |
20020058925 | Kaplan et al. | May 2002 | A1 |
20020065512 | Fjield et al. | May 2002 | A1 |
20020072768 | Ginn | Jun 2002 | A1 |
20020077656 | Ginn et al. | Jun 2002 | A1 |
20020077657 | Ginn et al. | Jun 2002 | A1 |
20020077658 | Ginn | Jun 2002 | A1 |
20020082641 | Ginn et al. | Jun 2002 | A1 |
20020087151 | Mody et al. | Jul 2002 | A1 |
20020099390 | Kaplan et al. | Jul 2002 | A1 |
20020103492 | Kaplan et al. | Aug 2002 | A1 |
20020111636 | Fleischman et al. | Aug 2002 | A1 |
20020111637 | Kaplan et al. | Aug 2002 | A1 |
20020111647 | Khairkhahan et al. | Aug 2002 | A1 |
20020128640 | Swanson | Sep 2002 | A1 |
20020133193 | Ginn et al. | Sep 2002 | A1 |
20020133227 | Murphy et al. | Sep 2002 | A1 |
20020147456 | Diduch et al. | Oct 2002 | A1 |
20020147461 | Aldrich et al. | Oct 2002 | A1 |
20020183823 | Pappu | Dec 2002 | A1 |
20020188318 | Carley et al. | Dec 2002 | A1 |
20030023141 | Stelzer et al. | Jan 2003 | A1 |
20030023262 | Welch | Jan 2003 | A1 |
20030023266 | Borillo et al. | Jan 2003 | A1 |
20030023267 | Ginn | Jan 2003 | A1 |
20030032858 | Ginn et al. | Feb 2003 | A1 |
20030045896 | Murphy et al. | Mar 2003 | A1 |
20030050630 | Mody et al. | Mar 2003 | A1 |
20030050632 | Fjield et al. | Mar 2003 | A1 |
20030050659 | Murphy et al. | Mar 2003 | A1 |
20030057156 | Peterson et al. | Mar 2003 | A1 |
20030065339 | Snyder et al. | Apr 2003 | A1 |
20030078598 | Ginn et al. | Apr 2003 | A1 |
20030078616 | Ginn et al. | Apr 2003 | A1 |
20030079753 | Vaska et al. | May 2003 | A1 |
20030083542 | Alferness et al. | May 2003 | A1 |
20030120337 | Van Tassel et al. | Jun 2003 | A1 |
20030125604 | Kochamba et al. | Jul 2003 | A1 |
20030158464 | Bertolero | Aug 2003 | A1 |
20030163143 | Wakabayashi | Aug 2003 | A1 |
20030163146 | Epstein et al. | Aug 2003 | A1 |
20030178033 | Cosgrove | Sep 2003 | A1 |
20030181901 | Maguire et al. | Sep 2003 | A1 |
20030181940 | Murphy et al. | Sep 2003 | A1 |
20030181942 | Sutton et al. | Sep 2003 | A1 |
20030181945 | Opolski et al. | Sep 2003 | A1 |
20030187362 | Murphy et al. | Oct 2003 | A1 |
20030191462 | Jacobs et al. | Oct 2003 | A1 |
20030191526 | Van Tassel et al. | Oct 2003 | A1 |
20030195560 | Ginn | Oct 2003 | A1 |
20030195561 | Carley et al. | Oct 2003 | A1 |
20030220667 | van der Burg et al. | Nov 2003 | A1 |
20030225443 | Kiran et al. | Dec 2003 | A1 |
20040009289 | Carley et al. | Jan 2004 | A1 |
20040010273 | Diduch et al. | Jan 2004 | A1 |
20040010285 | Carley et al. | Jan 2004 | A1 |
20040030335 | Zenati et al. | Feb 2004 | A1 |
20040034366 | van der Burg et al. | Feb 2004 | A1 |
20040039414 | Carley et al. | Feb 2004 | A1 |
20040044361 | Frazier et al. | Mar 2004 | A1 |
20040049210 | Van Tassel et al. | Mar 2004 | A1 |
20040064014 | Melvin et al. | Apr 2004 | A1 |
20040064138 | Grabek | Apr 2004 | A1 |
20040073241 | Barry et al. | Apr 2004 | A1 |
20040093025 | Egnelöv | May 2004 | A1 |
20040098031 | van der Burg et al. | May 2004 | A1 |
20040098042 | Devellian et al. | May 2004 | A1 |
20040122467 | VanTassel et al. | Jun 2004 | A1 |
20040127935 | VanTassel et al. | Jul 2004 | A1 |
20040127940 | Ginn et al. | Jul 2004 | A1 |
20040147969 | Mann et al. | Jul 2004 | A1 |
20040148019 | Vidlund et al. | Jul 2004 | A1 |
20040158287 | Cragg et al. | Aug 2004 | A1 |
20040167580 | Mann et al. | Aug 2004 | A1 |
20040175522 | Tajima | Sep 2004 | A1 |
20040186486 | Roue et al. | Sep 2004 | A1 |
20040215230 | Frazier et al. | Oct 2004 | A1 |
20040220560 | Briscoe | Nov 2004 | A1 |
20040225212 | Okerlund et al. | Nov 2004 | A1 |
20040232597 | Sjostedt et al. | Nov 2004 | A1 |
20040249342 | Khosravi et al. | Dec 2004 | A1 |
20040249412 | Snow et al. | Dec 2004 | A1 |
20040267193 | Bagaoisan et al. | Dec 2004 | A1 |
20040267307 | Bagaoisan et al. | Dec 2004 | A1 |
20040267308 | Bagaoisan et al. | Dec 2004 | A1 |
20050004641 | Pappu | Jan 2005 | A1 |
20050004652 | van der Burg et al. | Jan 2005 | A1 |
20050010252 | Ideker | Jan 2005 | A1 |
20050021016 | Malecki et al. | Jan 2005 | A1 |
20050033285 | Swanson et al. | Feb 2005 | A1 |
20050033287 | Sra | Feb 2005 | A1 |
20050033321 | Fleischman et al. | Feb 2005 | A1 |
20050038470 | van der Burg et al. | Feb 2005 | A1 |
20050049573 | VanTassel et al. | Mar 2005 | A1 |
20050049681 | Greenhalgh et al. | Mar 2005 | A1 |
20050070952 | Devellian | Mar 2005 | A1 |
20050085805 | Swanson | Apr 2005 | A1 |
20050085854 | Ginn | Apr 2005 | A1 |
20050085856 | Ginn | Apr 2005 | A1 |
20050113861 | Corcoran et al. | May 2005 | A1 |
20050113868 | Devellian et al. | May 2005 | A1 |
20050119695 | Carley et al. | Jun 2005 | A1 |
20050131503 | Solem | Jun 2005 | A1 |
20050149068 | Williams et al. | Jul 2005 | A1 |
20050149069 | Bertolero et al. | Jul 2005 | A1 |
20050149115 | Roue et al. | Jul 2005 | A1 |
20050149117 | Khosravi et al. | Jul 2005 | A1 |
20050154404 | Liddicoat et al. | Jul 2005 | A1 |
20050169974 | Tenerz et al. | Aug 2005 | A1 |
20050177180 | Kaganov et al. | Aug 2005 | A1 |
20050177182 | van der Berg et al. | Aug 2005 | A1 |
20050177183 | Thorne et al. | Aug 2005 | A1 |
20050177189 | Ginn et al. | Aug 2005 | A1 |
20050197716 | Sharkey et al. | Sep 2005 | A1 |
20050203410 | Jenkins | Sep 2005 | A1 |
20050203568 | van der Burg et al. | Sep 2005 | A1 |
20050222533 | Chanduszko et al. | Oct 2005 | A1 |
20050222614 | Ginn et al. | Oct 2005 | A1 |
20050234540 | Peavey et al. | Oct 2005 | A1 |
20050234543 | Glaser et al. | Oct 2005 | A1 |
20050245876 | Khosravi et al. | Nov 2005 | A1 |
20050245963 | Kida et al. | Nov 2005 | A1 |
20050267521 | Forsberg | Dec 2005 | A1 |
20050267528 | Ginn et al. | Dec 2005 | A1 |
20050273129 | Michels et al. | Dec 2005 | A1 |
20050273137 | Ginn | Dec 2005 | A1 |
20050277959 | Cosgrove et al. | Dec 2005 | A1 |
20050283187 | Longson | Dec 2005 | A1 |
20060004352 | Vaska et al. | Jan 2006 | A1 |
20060004388 | Whayne et al. | Jan 2006 | A1 |
20060009715 | Khairkhahan et al. | Jan 2006 | A1 |
20060009753 | Fjield et al. | Jan 2006 | A1 |
20060020162 | Whayne et al. | Jan 2006 | A1 |
20060020271 | Stewart et al. | Jan 2006 | A1 |
20060034930 | Khosravi et al. | Feb 2006 | A1 |
20060047313 | Khanna et al. | Mar 2006 | A1 |
20060058844 | White et al. | Mar 2006 | A1 |
20060074397 | Shimada | Apr 2006 | A1 |
20060074410 | Malecki et al. | Apr 2006 | A1 |
20060099238 | Khosravi et al. | May 2006 | A1 |
20060100664 | Pai et al. | May 2006 | A1 |
20060106442 | Richardson et al. | May 2006 | A1 |
20060135989 | Carley et al. | Jun 2006 | A1 |
20060136051 | Furst et al. | Jun 2006 | A1 |
20060149314 | Borillo et al. | Jul 2006 | A1 |
20060167484 | Carley et al. | Jul 2006 | A1 |
20060178694 | Greenhalgh et al. | Aug 2006 | A1 |
20060190014 | Ginn et al. | Aug 2006 | A1 |
20060190037 | Ginn et al. | Aug 2006 | A1 |
20060190038 | Carley et al. | Aug 2006 | A1 |
20060195123 | Ginn et al. | Aug 2006 | A1 |
20060195124 | Ginn et al. | Aug 2006 | A1 |
20060206109 | Swanson | Sep 2006 | A1 |
20060206121 | Chin et al. | Sep 2006 | A1 |
20060206148 | Khairkhahan et al. | Sep 2006 | A1 |
20060229672 | Forsberg | Oct 2006 | A1 |
20060229674 | Forsberg | Oct 2006 | A1 |
20060247672 | Vidlund et al. | Nov 2006 | A1 |
20060247680 | Amplatz et al. | Nov 2006 | A1 |
20060253037 | Ginn et al. | Nov 2006 | A1 |
20060253072 | Pai et al. | Nov 2006 | A1 |
20060253129 | Liddicoat et al. | Nov 2006 | A1 |
20060263418 | White | Nov 2006 | A1 |
20060265007 | White et al. | Nov 2006 | A1 |
20060271032 | Chin et al. | Nov 2006 | A1 |
20060271089 | Alejandro et al. | Nov 2006 | A1 |
20060287661 | Bolduc et al. | Dec 2006 | A1 |
20060287674 | Ginn et al. | Dec 2006 | A1 |
20070004984 | Crum et al. | Jan 2007 | A1 |
20070016228 | Salas | Jan 2007 | A1 |
20070032734 | Najafi et al. | Feb 2007 | A1 |
20070032823 | Tegg | Feb 2007 | A1 |
20070032824 | Terwey | Feb 2007 | A1 |
20070043344 | Mcauley | Feb 2007 | A1 |
20070060950 | Khosravi et al. | Mar 2007 | A1 |
20070060951 | Shannon | Mar 2007 | A1 |
20070066993 | Kreidler | Mar 2007 | A1 |
20070073313 | Liddicoat et al. | Mar 2007 | A1 |
20070073345 | Pipenhagen et al. | Mar 2007 | A1 |
20070083227 | van der Burg et al. | Apr 2007 | A1 |
20070083230 | Javois | Apr 2007 | A1 |
20070123817 | Khosravi et al. | May 2007 | A1 |
20070129758 | Saadat | Jun 2007 | A1 |
20070149988 | Michler et al. | Jun 2007 | A1 |
20070156010 | Aboul-hosn | Jul 2007 | A1 |
20070156084 | Belhe et al. | Jul 2007 | A1 |
20070156123 | Moll et al. | Jul 2007 | A1 |
20070162048 | Quinn et al. | Jul 2007 | A1 |
20070179345 | Santilli | Aug 2007 | A1 |
20070185530 | Chin-chen et al. | Aug 2007 | A1 |
20070198060 | Devellian et al. | Aug 2007 | A1 |
20070208329 | Ward et al. | Sep 2007 | A1 |
20070219546 | Mody et al. | Sep 2007 | A1 |
20070233226 | Kochamba et al. | Oct 2007 | A1 |
20070244476 | Kochamba et al. | Oct 2007 | A1 |
20070255314 | Forsberg | Nov 2007 | A1 |
20070260278 | Wheeler et al. | Nov 2007 | A1 |
20070265641 | Roue et al. | Nov 2007 | A1 |
20070270891 | Mcguckin | Nov 2007 | A1 |
20070276433 | Huss | Nov 2007 | A1 |
20070287999 | Malecki et al. | Dec 2007 | A1 |
20080004658 | Malecki et al. | Jan 2008 | A1 |
20080009843 | De La | Jan 2008 | A1 |
20080015569 | Saadat et al. | Jan 2008 | A1 |
20080033241 | Peh et al. | Feb 2008 | A1 |
20080033457 | Francischelli et al. | Feb 2008 | A1 |
20080039879 | Chin et al. | Feb 2008 | A1 |
20080045946 | Vaska | Feb 2008 | A1 |
20080058862 | Khosravi et al. | Mar 2008 | A1 |
20080058864 | Bagaoisan et al. | Mar 2008 | A1 |
20080071311 | White et al. | Mar 2008 | A1 |
20080082122 | Khosravi et al. | Apr 2008 | A1 |
20080097488 | Fleischman et al. | Apr 2008 | A1 |
20080097521 | Khosravi et al. | Apr 2008 | A1 |
20080109030 | Houser et al. | May 2008 | A1 |
20080114394 | Houser et al. | May 2008 | A1 |
20080125795 | Kaplan et al. | May 2008 | A1 |
20080125848 | Kusleika et al. | May 2008 | A1 |
20080132602 | Rizk et al. | Jun 2008 | A1 |
20080147097 | Liddicoat et al. | Jun 2008 | A1 |
20080167713 | Bolling | Jul 2008 | A1 |
20080167750 | Stahler et al. | Jul 2008 | A1 |
20080221593 | Liddicoat et al. | Sep 2008 | A1 |
20080243111 | Gammie et al. | Oct 2008 | A1 |
20080243183 | Miller et al. | Oct 2008 | A1 |
20080249397 | Kapadia | Oct 2008 | A1 |
20080269801 | Coleman et al. | Oct 2008 | A1 |
20080269802 | Coleman et al. | Oct 2008 | A1 |
20080272173 | Coleman et al. | Nov 2008 | A1 |
20080294088 | Solem et al. | Nov 2008 | A1 |
20080294175 | Bardsley et al. | Nov 2008 | A1 |
20080312664 | Bardsley et al. | Dec 2008 | A1 |
20080312676 | Solem | Dec 2008 | A1 |
20090005674 | Saadat et al. | Jan 2009 | A1 |
20090005777 | Houser et al. | Jan 2009 | A1 |
20090012354 | Wood | Jan 2009 | A1 |
20090012545 | Williamson, IV et al. | Jan 2009 | A1 |
20090088793 | Bagaoisan et al. | Apr 2009 | A1 |
20090112257 | Preinitz et al. | Apr 2009 | A1 |
20090143808 | Houser et al. | Jun 2009 | A1 |
20090254121 | Newth et al. | Oct 2009 | A1 |
20100312259 | Houser et al. | Dec 2010 | A1 |
20110144661 | Houser et al. | Jun 2011 | A1 |
Number | Date | Country |
---|---|---|
0047618 | Mar 1982 | EP |
0139 091 | May 1985 | EP |
0401525 | Dec 1990 | EP |
2007-516731 | Jun 2007 | JP |
782814 | Nov 1980 | SU |
1088709 | Apr 1984 | SU |
WO 9001497 | Feb 1990 | WO |
WO 9115155 | Oct 1991 | WO |
WO 0197696 | Dec 2001 | WO |
WO 03096881 | Nov 2003 | WO |
WO 03096881 | Apr 2004 | WO |
Entry |
---|
International search report and written opinion dated Mar. 8, 2011 for PCT Application No. US2010/030531. |
International search report and written opinion dated Jul. 27, 2011 for PCT Application No. US2010/056059. |
Office action dated Jan. 22, 2013 for U.S. Appl. No. 12/563,320. |
Office action dated Jan. 24, 2012 for U.S. Appl. No. 12/563,297. |
Office action dated Feb. 7, 2005 for U.S. Appl. No. 10/224,659. |
Office action dated Mar. 15, 2012 for U.S. Appl. No. 12/561,104. |
Office action dated Mar. 17, 2008 for U.S. Appl. No. 11/279,242. |
Office action dated Apr. 6, 2009 for U.S. Appl. No. 11/279,242. |
Office action dated Apr. 14, 2011 for U.S. Appl. No. 10/831,850. |
Office action dated Apr. 19, 2012 for U.S. Appl. No. 12/563,371. |
Office action dated May 2, 2007 for U.S. Appl. No. 11/279,242. |
Office action dated May 15, 2007 for U.S. Appl. No. 10/785,486. |
Office action dated Jun. 18, 2012 for U.S. Appl. No. 12/563,320. |
Office action dated Jun. 19, 2012 for U.S. Appl. No. 11/930,111. |
Office action dated Jul. 22, 2005 for U.S. Appl. No. 10/224,659. |
Office action dated Jul. 26, 2012 for U.S. Appl. No. 12/167,212. |
Office action dated Aug. 24, 2012 for U.S. Appl. No. 12/563,297. |
Office action dated Sep. 13, 2006 for U.S. Appl. No. 10/785,486. |
Office action dated Sep. 23, 2011 for U.S. Appl. No. 11/933,129. |
Office action dated Oct. 15, 2008 for U.S. Appl. No. 10/785,486. |
Office action dated Nov. 13, 2008 for U.S. Appl. No. 11/279,242. |
Office action dated Nov. 29, 2011 for U.S. Appl. No. 12/327,655. |
Office action dated Dec. 12, 2007 for U.S. Appl. No. 10/785,486. |
U.S. Appl. No. 13/786,375, filed Mar. 5, 2013, Houser et al. |
Office action dated Mar. 5, 2013 for U.S. Appl. No. 12/563,297. |
Office action dated Mar. 28, 2013 for U.S. Appl. No. 12/757,275. |
Office action dated Mar. 29, 2013 for U.S. Appl. No. 12/942,914. |
Office action dated Jun. 24, 2013 for U.S. Appl. No. 12/757,275. |
Office action dated Aug. 14, 2013 for U.S. Appl. No. 11/279,242. |
Office action dated Oct. 7, 2013 for U.S. Appl. No. 12/563,297. |
Office action dated Oct. 22, 2013 for U.S. Appl. No. 12/563,338. |
Office action dated Nov. 19, 2013 for U.S. Appl. No. 12/942,914. |
International Search Report dated Jul. 12, 2004 for PCT/US2004/040933. |
Number | Date | Country | |
---|---|---|---|
20090143789 A1 | Jun 2009 | US |
Number | Date | Country | |
---|---|---|---|
61005435 | Dec 2007 | US |